Clinical Rheumatology最新文献

{"title":"Biosimilars and reference biological medicines in the treatment of rheumatoid arthritis: a multicenter cross-sectional study in Catalonia, Spain.","authors":"Joan Mas Marin, Marina Molina-Olano, Nuria Rudi Sola, Núria Miserachs-Aranda, Paula Montoliu Alcón, Jan T De Pourcq, Carles Quiñones Ribas, Laura Borràs Trias, Eva Fernández-Cañabate, Juan González-Valdivieso, Carlos Figueiredo-Escribá, René Delgado-Hernández, Antonio J Braza, Cecilia F Lastra, Eduardo L Mariño, Pilar Modamio","doi":"10.1007/s10067-025-07568-9","DOIUrl":"10.1007/s10067-025-07568-9","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study is to compare the effectiveness of reference biologic medicines used in the treatment of rheumatoid arthritis (RA) specifically adalimumab, etanercept, and infliximab, with corresponding biosimilar medicines, based on an exploratory analysis of clinical data obtained in patients treated with these medicines in five hospitals in the region of Catalonia, Spain.</p><p><strong>Methods: </strong>There is a consultation of the database of the Registry of Patients and Treatments of the Catalan Health Service: extraction of data from adult patients diagnosed with moderate and severe active RA and with active prescription of at least one biological drug (reference or biosimilar) or JAK inhibitor. To compare the effectiveness of each reference biologic with its biosimilar, differences in mean DAS28-ESR values before and after treatment were assessed for adalimumab and its biosimilar, etanercept and its biosimilar, and infliximab and its biosimilar.</p><p><strong>Results: </strong>The study consisted of 643 patients. The most dispensed medicines were anti-TNFs, with 303 patients on treatment. Thirty-six percent of all patients were using biosimilars. No statistically significant differences were observed in any of the three comparisons between the reference biologic medicine and its biosimilar. These findings suggest that biosimilars have comparable effectiveness to reference biologics in reducing DAS28-ESR; in addition, they can provide substantial savings to public health systems.</p><p><strong>Conclusions: </strong>A significant number of patients diagnosed with moderate to severe active RA were treated with biological medicines and receiving the available biosimilar treatments. Future research should be conducted to confirm comparable effectiveness found to their reference biologic medicines in this exploratory analysis. Key Points • Biosimilar use: 36% of rheumatoid arthritis (RA) patients in Catalonia are treated with biosimilars, exceeding the 12% recommendation. This reflects growing acceptance of these alternatives. • Comparative effectiveness: Biosimilars of adalimumab, etanercept, and infliximab showed comparable therapeutic benefit to their reference biologics in reducing disease activity in active rheumatoid arthritis. • Real-world data: The study provides real-world data from five hospitals, making biosimilar medicines a viable choice for rheumatologists in routine rheumatoid arthritis management.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3445-3458"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12397168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the coalescent lung ultrasound score in rheumatoid arthritis-associated interstitial lung disease.","authors":"Zeynep Tüzün, Kaniye Aydın, İpek Türk, Gizem Varkal, Gizem Kırmızıer, Hasan Doğru, Ferhat Can Pişkin, Didem Arslan","doi":"10.1007/s10067-025-07589-4","DOIUrl":"10.1007/s10067-025-07589-4","url":null,"abstract":"<p><strong>Objective: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that can present with extra-articular findings. RA-associated interstitial lung disease (RA-ILD) is the most prominent extra-articular finding and is important because it contributes significantly to morbidity and mortality. The aim of this study was to determine the role of lung ultrasonography (LUS) in diagnosing RA-ILD and assessing the severity of involvement.</p><p><strong>Method: </strong>The study included 69 patients aged 18 years and older who met the ACR/EULAR 2010 RA classification criteria. LUS was performed on the patients by an experienced, blinded specialist and the findings were compared with the high-resolution computed tomography (HRCT) Warrick score evaluated by an experienced radiologist.</p><p><strong>Results: </strong>A statistically significant correlation was found between modified LUS scores and Warrick scores (r: 0.838). Among the patients screened with USG, USG ILD findings were detected in 35 patients with RA-ILD diagnosis (100%) and 1 of the 34 controls (2.9%). LUS was false positive in only 1 RA patient (p < 0.001).</p><p><strong>Conclusion: </strong>In conclusion, USG can be considered as a method correlated with CT in assessing the degree of lung involvement. However, USG cannot distinguish malignant nodules, infectious disease or drug adverse reactions. HRCT is a reliable method for the primary differential diagnosis of lung involvement. According to our study, LUS can prolong the CT scan intervals in patients with stable clinical conditions and no obvious symptoms, thereby reducing unnecessary radiation exposure. Key Points • RA with interstitial lung disease • LUS in interstitial lung disease.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3459-3465"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-omics identification of circulating protein biomarkers for intervertebral disc degeneration using Mendelian randomization and scRNA-seq.","authors":"Fan Bai, Lingting Wang, He Liu, Yufei He, Hong Wang","doi":"10.1007/s10067-025-07606-6","DOIUrl":"10.1007/s10067-025-07606-6","url":null,"abstract":"<p><strong>Background: </strong>Intervertebral disc degeneration (IVDD) is a primary cause of chronic low back pain, significantly impacting quality of life and healthcare systems globally. Despite its prevalence, the molecular mechanisms underlying IVDD remain unclear, and effective biomarkers are lacking. This study aims to identify circulating protein biomarkers causally linked to IVDD and explore their potential as biomarkers.</p><p><strong>Methods: </strong>A proteome-wide Mendelian randomization (MR) analysis was conducted using data from 4907 circulating proteins to assess their causal relationships with IVDD, utilizing the FinnGen cohort. Single-cell RNA sequencing (scRNA-seq) was performed to evaluate the expression patterns of identified proteins in healthy and degenerated disc tissues. Additionally, machine learning models were employed to rank these proteins based on their therapeutic potential.</p><p><strong>Results: </strong>Eight circulating proteins (CD96, CDH3, COPS2, DDX23, FAM210A, PNPO, STOML2, and UBE2D2) were identified as statistically associated with IVDD. scRNA-seq analysis demonstrated differential expression patterns between healthy and degenerated tissues, with COPS2 and UBE2D2 achieving the highest classification accuracy for distinguishing tissue states (AUC = 0.85). Functional and pathway analyses highlighted their roles in inflammation, extracellular matrix regulation, and cellular stress responses.</p><p><strong>Conclusions: </strong>This study integrates multi-omics approaches to uncover novel protein biomarkers for IVDD, with COPS2 and UBE2D2 showing promising potential as biomarkers or mechanistic targets. Further in vivo validation studies are warranted to confirm their clinical relevance and therapeutic applicability. Key Points • This study utilized Mendelian randomization and single-cell RNA sequencing to identify eight circulating proteins causally associated with IVDD. • The application of machine learning models revealed COPS2 and UBE2D2 as top contributors with high classification accuracy in distinguishing healthy and degenerated disc tissues. • Comprehensive multi-omics and pathway analysis highlighted COPS2 and UBE2D2 as promising therapeutic targets for IVDD, warranting further in vivo validation. • Enrichment analyses identified significant immune-related pathways, underscoring inflammation's critical role in IVDD progression and providing avenues for targeted interventions.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3697-3710"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Predictors of Residual Symptoms in Rheumatoid Arthritis Patients in SDAI Remission: A Cross-Sectional Study Using the Illustrated Okomarigoto Sheet.","authors":"Kensuke Koyama, Tetsuro Ohba, Ryousuke Koizumi, Hirotaka Haro","doi":"10.1007/s10067-025-07592-9","DOIUrl":"10.1007/s10067-025-07592-9","url":null,"abstract":"<p><strong>Objectives: </strong>This study investigated residual symptoms in patients with rheumatoid arthritis (RA) who had achieved remission based on the Simplified Disease Activity Index (SDAI) using the \"Okomarigoto sheet\" (OS) assessment tool.</p><p><strong>Methods: </strong>The OS measures morning stiffness, pain, and fatigue through five questions. Each item was rated from 0 (none) to 2 (severe), yielding a total score between 0 and 30, with higher scores indicating greater symptom severity. OS scores were evaluated in 200 patients in SDAI remission. Patients were classified based on OS scores (0 vs. non-zero), and regression analysis was conducted to identify factors associated with residual symptoms.</p><p><strong>Results: </strong>Residual symptoms were observed in 61.5% of patients. The most persistent symptoms were morning stiffness (27%), pain (21.5%), and fatigue (23%). Significant predictors of a non-zero OS score included female sex (OR 2.70, 95%CI 1.27-5.73), disease duration (OR 0.96, 95%CI 0.92-0.99), tender joint counts (OR 5.75, 95%CI 1.15-28.9), and Patient Global Assessment (OR 2.91, 95% CI 1.32-6.38).</p><p><strong>Conclusions: </strong>The OS effectively detected residual symptoms in RA patients who had reached SDAI remission. Incorporating OS into patient-reported outcome measures and shared decision-making may enhance treatment strategies and improve patient satisfaction.</p><p><strong>Key points: </strong>• Utilizing a novel patient-reported outcome assessment tool incorporating illustrations and onomatopoeia for individuals with rheumatoid arthritis, 61.5% of patients were identified as experiencing residual symptoms despite achieving remission according to the Simplified Disease Activity Index. Risk factors for residual symptoms identified through the Okomarigoto sheet included female sex, the number of tender joints, and the patient global assessment.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":"3497-3504"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Split vs single-dose oral methotrexate in rheumatoid arthritis: a randomized controlled trial (SMART study).","authors":"Chandra Bhushan Prasad, Varun Dhir, Ranjan Gupta, Koshy Nithin Thomas, Phani Kumar Devarasetti, Venkatesh Srinivasa Pai, Avinash Jain, Gsrsnk Naidu, Priya Saini, Bidyalaxmi Leishangthem, Aastha Khullar, Ramesh Manthri, Shefali Khanna Sharma, Aman Sharma, Amita Aggarwal, Sanjay Jain","doi":"10.1007/s10067-025-07646-y","DOIUrl":"https://doi.org/10.1007/s10067-025-07646-y","url":null,"abstract":"<p><strong>Objective: </strong>Pharmacokinetic evidence suggests split dose of oral methotrexate increases bioavailability, but unproven to improve efficacy. Thus, we planned to compare clinical response of split vs single-dose oral methotrexate in rheumatoid arthritis (RA).</p><p><strong>Methods: </strong>This pragmatic, open-label (blinded assessor) randomized controlled trial was conducted across six university hospitals in India and enrolled patients with seropositive RA with active disease (TJC₂₈ ≥ 4 and SJC₂₈ ≥ 2). They were randomized 1:1 to split-dose (15 mg morning, 10 mg evening) or single-dose (25 mg) once weekly oral methotrexate for 16 weeks, after which a second DMARD could be added. Primary outcome and key secondary outcomes were EULAR good response at 24 weeks and 16 weeks respectively. Analysis was by intention-to-treat with non-response imputation. Clinical Trials Registry-India CTRI/2021/02/031361.</p><p><strong>Results: </strong>Two hundred fifty-three patients [83% female, mean age 42.2 years, mean disease duration 2.1 yrs] were randomized to receive either split-dose (n = 128) or single-dose (n = 125) methotrexate. Primary outcome, good response at 24 weeks, was not significantly higher with split-dose methotrexate (+ 6.5%, 95% CI - 4.2 to 17.2%, p = 0.263). However, key secondary outcome, good response at 16 weeks, was significantly higher with split-dose methotrexate (+ 12.3%, 95% CI 3.5 to 21.3%, p = 0.008). Also, less patients in split-dose group required addition of second DMARD at 16 weeks (- 19.5%, p = 0.003). Numerically higher transaminitis and intolerance occurred with split-dose MTX.</p><p><strong>Conclusion: </strong>Although the primary outcome was not met, we found faster response and better efficacy at 16 weeks with split-dose oral MTX, and reduced need for a second DMARD. Key Points • This was the first RCT to compare split-dose (same-day, morning, evening) to single-dose oral methotrexate (MTX) and included 253 patients of RA. • Primary outcome was not met, i.e., split-dose MTX was not superior in terms of EULAR good response at 24 weeks. • However, key secondary outcome was met, i.e., split-dose MTX met led to significantly higher EULAR good response at 16 weeks; also it reduced need for addition of a second DMARD. • Split-dose MTX was associated with higher adverse effects (numerically) in terms of both intolerance and transaminitis.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-omics characterization of gut microbiota and fecal and plasma metabolites in patients with primary Sjögren's syndrome.","authors":"Yuanyuan Liu, Qi Wang, Yan Zhang, Ruixue Duo, Xueting Bian, Jingjing Tian, Jiayao Hao, Jianxiong Zheng, Haili Shen","doi":"10.1007/s10067-025-07642-2","DOIUrl":"https://doi.org/10.1007/s10067-025-07642-2","url":null,"abstract":"<p><strong>Introduction: </strong>Accumulating evidence has implicated gut microbiota and their metabolites in primary Sjögren's syndrome (pSS) pathogenesis. However, no study simultaneously explores the gut microbiome, microbial, and plasma metabolome in pSS patients.</p><p><strong>Method: </strong>Thirty pSS patients and 60 healthy controls (HCs) were recruited. Shotgun metagenomic sequencing and untargeted metabolomics were performed on stool and plasma samples.</p><p><strong>Results: </strong>pSS patients exhibited significant reduction in microbial richness and diversity. Bacteroidetes and Firmicutes accounted for over 80% of all phyla. Four phyla, 48 genera, and 106 species with significant differences were identified (P < 0.05). Proteobacteria, Ascomycota, Fusobacteria, and 31 genera (e.g., Escherichia, Veillonella, Prevotella, Klebsiella) were enriched in pSS, while Actinobacteria, Bifidobacterium, Dorea, and Blautia were depleted. Opportunistic pathogens (e.g., Escherichia coli, Prevotella copri, Streptococcus oralis, Klebsiella pneumoniae, Enterococcus faecalis) and pathogenic Clostridium bolteae and Fusobacterium nucleatum were more abundant in pSS, whereas beneficial Bifidobacterium longum and butyrate-producing Eubacterium hallii and Anaerostipes hadrus were in HCs. Notably, Lactobacillus spp. were enriched in pSS. Of 298 differential functional pathways, 239 pSS-enriched pathways were focused on nutrient and energy metabolism, while amino acid biosynthesis in HCs. During 881 differential fecal metabolites (pSS: HCs = 631:250), fatty acyls were enriched in pSS, and glycerophospholipids in HCs. Among the 712 differential plasma metabolites (pSS: HCs = 438:274), heterocyclic compounds and benzene derivatives were more abundant in pSS, while fatty acyls and glycerophospholipids prevailed in HCs. Amino acids and organic acids were predominant in both samples.</p><p><strong>Conclusions: </strong>This study characterized gut microbiome and fecal/plasma metabolome in pSS patients, providing theoretical support for regional pSS prevention and treatment. Key Points • This is the first study to systematically characterize the gut microbiome and fecal and plasma metabolomes of primary Sjögren's syndrome (pSS) patients in Northwest China via multi-omics integration analysis. • Significant reduction in gut microbial diversity and probiotic bacteria, enrichment of opportunistic and infectious pathogens, and microbial dysfunction were observed in pSS patients. • Much more differential fecal and plasma metabolites were observed in pSS patients, with amino acids, organic acids and derivatives, nucleotides, and metabolites being the main altered metabolites in both samples.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Methodological scrutiny of Prevotella's role in methotrexate-induced enteropathy through PI3K/AKT signaling.","authors":"Qin Li, Guangzhao Zhu","doi":"10.1007/s10067-025-07667-7","DOIUrl":"https://doi.org/10.1007/s10067-025-07667-7","url":null,"abstract":"","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective natural history study in adult and juvenile patients with incident dermatomyositis and polymyositis using real world data.","authors":"David M Barnes, Daniela Graham, Cecilia E Borlenghi, Thomas Edwards, Stephen E Schachterle, Helen Sile","doi":"10.1007/s10067-025-07614-6","DOIUrl":"https://doi.org/10.1007/s10067-025-07614-6","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective natural history study used real-world data to describe baseline demographics, comorbidities, clinical characteristics, and treatments, and assess incidence rates (IRs) of extra-muscular outcomes in patients with incident dermatomyositis (DM), polymyositis (PM), juvenile DM (JDM), and juvenile PM (JPM).</p><p><strong>Methods: </strong>De-identified clinical data were collected from the US Optum® electronic health records with supplemental claims (01 January 2016 to 31 March 2021). Total 9,009 patients were included (DM: 4,275; PM: 4,559; JDM: 128; JPM: 47). IRs of 13 outcomes were estimated in patients and an equal number of sex- and age-matched controls (MCs) without DM/PM.</p><p><strong>Results: </strong>Mean age at index was 54.5 (DM), 57.3 (PM), 14.3 (JDM), and 15.1 years (JPM). Most common comorbidities were hypertension in DM (50.3%) and PM (63.9%) cohorts, dysphagia in JDM (15.6%) and liver disease in JPM (23.4%) cohorts. Most common clinical characteristics were Raynaud's phenomenon in DM (8.6%), PM (7.9%), and JDM (11.7%) cohorts, and arthritis in JPM (10.6%) cohort. Systemic steroids were the most frequent medication (DM: 70.3%; PM: 68.3%; JDM: 73.4%; JPM: 59.6%). IRs (per 100 person years) of outcomes in all cohorts were higher in patients versus their MCs. In DM and PM cohorts, highest IRs were observed for gastroesophageal reflux disease (DM:10.3; PM:12.8). In JDM cohort, dysphagia (4.3) had highest IR. In JPM cohort, cardiac dysrhythmia (3.5) had highest IR.</p><p><strong>Conclusion: </strong>This study addresses existing gaps in understanding the descriptive epidemiology of DM and PM in the US, particularly the IRs of extra-muscular disease manifestations and malignancy events.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to letter to editor regarding \"Comparison of intra-articular ozone and steroid injection in patients with adhesive capsulitis\".","authors":"Aylin Ayyıldız, Ali Sahillioğlu, Tülay Şahin","doi":"10.1007/s10067-025-07661-z","DOIUrl":"https://doi.org/10.1007/s10067-025-07661-z","url":null,"abstract":"","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extra Virgin Olive Oil alleviates articular cartilage damage and reduces ox-LDL and oxidative stress in monosodium iodoacetate-induced osteoarthritis in rats.","authors":"Cemil Erturk, Sabri Kerem Diril, Gülay Yuzbasioglu Ozturk, Ahmet Gulcubuk, Duygu Sultan Oran, Ozge Erdogan Bamac, Nilgun Isiksacan","doi":"10.1007/s10067-025-07621-7","DOIUrl":"https://doi.org/10.1007/s10067-025-07621-7","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the therapeutic effects of extra virgin olive oil (EVOO), known for its antioxidant and cytoprotective properties, in a monosodium iodoacetate (MIA)-induced rat model of osteoarthritis (OA).</p><p><strong>Methods: </strong>Twenty-one male Wistar rats were randomly divided into three groups: Control, OA, and EVOO-treated. OA was induced via intra-articular injection of MIA. The EVOO Group received a diet supplemented with EVOO for 21 days post-induction. Histopathological, immunohistochemical, biochemical, and radiological analyses were performed to evaluate cartilage damage, inflammation, apoptosis and oxidative stress.</p><p><strong>Results: </strong>Histopathological evaluation revealed moderate cartilage destruction and synovitis in the OA Group, which were reduced in the EVOO-treated Group. Safranin-O staining confirmed higher proteoglycan preservation with EVOO supplementation. Immunohistochemistry demonstrated low intensity of oxidized low-density lipoprotein (ox-LDL) in the EVOO-treated Group compared to the OA Group. TUNEL staining indicated a significant reduction in chondrocyte apoptosis in EVOO-fed rats. Biochemically, ox-LDL and other oxidative stress markers, including total oxidative status (TOS) and oxidative stress index (OSI), were significantly reduced in the EVOO Group compared to the OA Group (p < 0.05). In contrast, the antioxidant capacity (TAC) level was significantly higher in the EVOO Group (p < 0.05). A positive correlation was observed between ox-LDL and TOS (p = 0.005).</p><p><strong>Conclusions: </strong>Our findings suggest that EVOO may contribute to cartilage preservation and reduce synovitis in rats with MIA-induced OA. Additionally, EVOO exhibits significant antioxidant effects by reducing ox-LDL and oxidative stress markers and enhancing antioxidant capacity. These results may highlight EVOO as a potential adjuvant therapy for managing OA. Key Points • This study evaluates the therapeutic effects of extra virgin olive oil (EVOO) in a monosodium iodoacetate (MIA)-induced rat model of osteoarthritis (OA). • EVOO supplementation reduced cartilage destruction, synovitis, and chondrocyte apoptosis, while preserving proteoglycan content in the cartilage matrix, as demonstrated by histopathological and immunohistochemical findings. • Significant reductions in oxidized low-density lipoprotein (ox-LDL) and other oxidative stress markers, including total oxidative status (TOS), and oxidative stress index (OSI), were observed in EVOO-fed rats, as confirmed by biochemical analyses. • EVOO shows potential as an adjuvant therapy for managing osteoarthritis due to its antioxidant and cartilage-protective properties.</p>","PeriodicalId":10482,"journal":{"name":"Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}